-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JO0hZsdktzb0W0WyHlV0Ojot2xEiA5GD6Vs8ceZCEeO64smzmV8hFQHLKNtHnXAL
 CJ2jVSamnlrk5+xDNRzORQ==

<SEC-DOCUMENT>0001129928-09-000023.txt : 20090427
<SEC-HEADER>0001129928-09-000023.hdr.sgml : 20090427
<ACCEPTANCE-DATETIME>20090427144206
ACCESSION NUMBER:		0001129928-09-000023
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090427
FILED AS OF DATE:		20090427
DATE AS OF CHANGE:		20090427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09772321

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K FORM
<TEXT>
<html>
  <head>
    <title>form6-k.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>&#160;</div>
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule&#160;13a-16 or 15d-16</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
the Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the
month of&#160;April 2009</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
File Number 000-31062</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Oncolytics
Biotech Inc.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite&#160;210,
1167 Kensington Crescent NW</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta, Canada T2N 1X7</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&#160;20-F or Form&#160;40-F.</font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form&#160;6-K in paper as
permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">NUMBER</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td valign="top" width="7%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="69%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">News
      Release Dated April 27, 2009 -&#160;Oncolytics Biotech&#174; Inc. to Present at
      BioFinance 2009</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">
          <tr>
            <td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" colspan="3" valign="top" width="39%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Registrant)</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="38%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date:&#160;&#160;April
      27, 2009</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="2%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
            </td>
            <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            <td align="left" valign="top" width="36%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">/s/&#160;&#160;Doug
      Ball</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Doug
      Ball</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Chief
      Financial Officer</font></div>
            </td>
          </tr>
      </table>
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br><br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div><img src="ex9910.jpg" alt=""><br>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">210, 1167
Kensington Cr. N.W</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary,
Alberta</font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Canada
T2N 1X7</font><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;F</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OR
IMMEDIATE RELEASE</font><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Oncolytics Biotech</font>&#174;<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Inc. </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">to Present at BioFianance
2009</font></font><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><br></font></font>

            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: normal"><font style="DISPLAY: inline; FONT-WEIGHT: normal">CALGARY, Alberta, --- April 27,
2009</font> &#8211; Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc.
(TSX: ONC, NASDAQ: ONCY), is scheduled to present a corporate overview of the
Company at BioFinance 2009 on <font style="DISPLAY: inline; FONT-WEIGHT: normal">Wednesday, April 29 at 9:00 a.m.
(ET)</font>.&#160;&#160;The conference will be held at the Toronto Marriott
Eaton Centre from April 28-30, 2009.</font></font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">About
BioFinance</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">BioFinance
2009 is the leading investor conference in Canada for the life sciences
industry. This three-day event brings together key industry players interested
in investment opportunities and issues affecting companies in the life sciences
sector.</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">About
Oncolytics Biotech Inc.</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-WEIGHT: normal">Oncolytics is a Calgary-based biotechnology company
focused on the development of oncolytic viruses as potential cancer
therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of
Phase I/II and Phase II human trials using REOLYSIN&#174;, its proprietary
formulation of the human reovirus, alone and in combination with radiation or
chemotherapy.&#160;&#160;For further information about Oncolytics, please visit
<font style="DISPLAY: inline; FONT-WEIGHT: normal; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font></font></font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">The
presentation time is subject to change. This release and the presentation
related thereto contain forward-looking statements which involve known and
unknown risks, delays, uncertainties and other factors not under the Company&#8217;s
control and which may cause actual results, performance or achievements of the
Company to be materially different from the results, performance or expectations
implied by these forward-looking statements. Such risks and uncertainties
include, among others, the efficacy of REOLYSIN as a cancer treatment, the
success and timely completion of clinical studies and trials, uncertainties
related to the research and development of pharmaceuticals, uncertainties
related to the regulatory process and general changes to the economic
environment. Investors should consult the Company&#8217;s quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except as
required by applicable laws.</font></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR
FURTHER INFORMATION PLEASE CONTACT:</font></div>
            <div>
              <table cellpadding="0" cellspacing="0" width="100%">
                  <tr>
                    <td align="left" valign="top" width="23%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc.</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cathy
      Ward</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210,
      1167 Kensington Cr NW</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      Alberta T2N 1X7</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.670.7377</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.283.0858</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">cathy.ward@oncolytics.ca</font></font></div>
                      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                    </td>
                    <td align="left" valign="top" width="24%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Equicom Group</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nick
      Hurst</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">325,
      300 5th Ave. SW</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary,
      AB, T2P 3C4</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:
      403.538.4845</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:
      403.237.6916</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
                      <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
                    </td>
                    <td align="left" valign="top" width="28%">
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The
      Investor Relations Group</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Erika
      Moran</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11
      Stone St, 3rd Floor</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New
      York, NY&#160;&#160;10004</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:&#160;&#160;212.825.3210</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;212.825.3229</font></div>
                      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">emoran@inve</font><font style="DISPLAY: inline">storrelationsgroup.com</font></font></div>
                    </td>
                  </tr>
              </table>
            </div>
            <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-30-</font></div>
            <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br><br><br></div>
        </div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      </div>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex9910.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex9910.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8T+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`%$!
M4P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHK+\9^,_#'P]\,WOC/QIKUII>E:;;M/?ZA>S!(H8QU8D_RZ
MDD`<FDW8#1>9%&<YK$\;?%#X>?#73UU7XA^.-(T.V9E5;C5M2BMD))P!F1@.
M37P+\:?^"G/[0W[1OQ-N/@3_`,$__!$T\9D:-/$XM`]Q<(,!ID$H$5K%UP\F
M21@C:>"SX>?\$8/B-\4-03QQ^UU^T'?7.H7`,EW9Z7.UW<JS;\J;JXW*"/E/
MRH1G(R?O'SY8V567+AX<WGLC14[?$['U(W_!3']A)',;_M'Z)D$CB&<^W_/*
MMKP/^W=^Q[\2=4_L;P?^T)X:N+HNB)#/>_9C(SMM54\X)O8GC:N37E=C_P`$
M8?V'X+&&WN_#WB"YECB59+F3Q).K2D#EB$(4$GG``'/`K#^)7_!$;]E#Q+H@
MM_`.K^(O#%\F[9=KJ!O8WR`,/'-U`Y^ZRGGJ>E+GS)?9C][$U2?<^QK+4;+4
M;=;NRNHY8G&4EB<,K#V(X/X5,&5NAS7Y7^._V;_V\?\`@F/K'_"R?@MX^N?$
MO@NWD#7B6B2/;I"'7"7=FQ(13N(\R(Y&6.Y,\_5O[#'_``4T^&/[5\4/@CQ+
M!%X=\<%';^Q'D9H;U4QF2VD(`8X.3&?G`4G!`W5I2QT)5/9U$XR\^OH$J;2N
MM3ZDHI$;<H;'44M=Q`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`#96`4[B`,<DG
MI7Y@_M:?&+XG_P#!33]I>#]D?]GV5[;POH%Y-_:-_+=8M[HQ2*DE]*JGF*,\
M1)R69\XR1M^N/^"FW[0NH?L\?LG:WKGAV]^SZUKCKHVCR@L&CDG!#R*5'#)$
M)&!XY4<UQO\`P1[_`&;[#X1_LPV_Q-U&TQK?CHK?SRNF&CLURMO&/]DKF7/\
M7F@GH,>9BF\366'CMO+T[&L;07,>W_LQ_LM_"O\`93^'<?P_^&&CK&)2)=4U
M&7+7%_/C!ED<DGV5<[5'`KTN@#`Q17HPA&G%1BK)&3;;NPHHHJ@&RQ+,A1L8
M(P01G-?GY_P4R_X)X>'_``GX:D_:E_9>T"70M<T*[6^UJPT-FC!A7&;JWC08
MBDC/[QBN`5#,1D<_H+4-_9VM_;/97MO'-#*C)+#*@974C!4@]00<8KGQ-"%>
M'*]^C[#BW%W1\W_\$U/VT%_:U^#[6_BIBOBWPRD-KX@+%!]MW*?+O$"@`*^&
MR,8#!ATQ7TM7Y8^,O!K_`/!-O_@IYX=U#P1.T/A'Q;<QLEDA5MMC=S>3-;E`
M5P(Y@&3H`%09.&!_4N)MV>.AK#`5IU(.G/XHNS*J12=UU'T445WD!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110!^='_!=?6)[_6?A;\-I(D6TNYK^Y>=`?,5MUO#@=L8D
M)Z=0.W%?H'X+\-:=X,\):;X3TE0+;3;"&U@^15^1$"CA0`.!V`%?GQ_P70T^
M_L/&?PJ\;7-MMTVW-]!-<!P=K^9;R8V_>/RHQX';'7`/Z'^'M6LM=T2TUK39
M2]M=VT<UO(5(W(RAE.#R.#TKS<,D\=6;\OR-)_!$N4445Z1F%%%%`!1110!\
M`?\`!>;PAHTGPQ\">/6@(U*#7Y]/CF7`_<20-*RGC)PT*D<\9;^\:^SOV>]:
MU3Q+\"_!OB37+QKB\O\`PIIT]W,R@&21[:-F;"@`9)/0"OCS_@O%K&FQ_!?P
M-H4EX@O)O%4MQ%;[OF>*.UD1W`[A6DC!]W%?7G[-D%U8?L]^!;"^M)(9H?!V
MF)+#,A1T86T8*LI&5((Y!KSZ7^_U?1?J5_R[B>/?\%1?VG_BO^RG\$M%\>?"
M*YT^'4+_`,41V$[ZC9>>GDM;SR$!<C!W1KSZ9KSO]A__`(*;>)?&_CH?`?\`
M:XMK#1?$VH>5/X;UFVB$%GJ4<R"2&,\E075E:.0$K(&`X;&Y_P#P78_Y-?\`
M"_\`V/</_I'=U0\??\$]O"W[7/[$?PT\8^$#;Z1X]TKX>Z6-+U/[B7R+:H5M
MK@CMG[DG5">ZY%85GB?KDG3=[+;OY%+E<+,^COVU?B1\2?A#^S'XL^*'PJU2
MPM=9T'3Q>Q2ZE:>=$T:2*9$V9&69-P!)X)%<K_P32_:(^)G[3_[-Q^)WQ9N[
M&;53K]W9[M/LO(C\J,1E?ER><L>:^-[#]NGX@77[+'Q-_8M_:LL+VT\::7X8
MN[72-2U'B6Z\I0WV:<L?FE"+E)`2)1CDG!;Z0_X(F+N_8I7G_F;=0_E%54L5
M[?%QY6[6=UYI@X*$+-'U9XD\3:#X-T2\\2^*-5M['3["V>>]O+J4)%#&HRS,
MQX``%?'%E^W?^T[^V#XQU#P=^P1\-M+M-$T>ZV:CX]\9,WD-AAA4A494NOS*
M#N8C.1'C->D_\%6?"7CWQK^Q3XJTCX?12S30M:W6HV=O;&62YLXIU>5%`!/&
M!(2.<1FO-/\`@B/\0?AE=?LX7GPYT76XE\3VNNW5[K&F3WBF:2-_+6.X2,<K
M$5")G^^K'/(K2M4F\4J*?*FK_P##,2BE&YW-U\-_^"K-B9]3M/VC/A=>R^4#
M%I\GA*>.)V7<0H;<2F[(!8[L``@<'/MWP/E^.-QX,2Z_:!M_#,.OR3.9+;PI
MY[6L,><*N^9BTC'DDX4#.`.,GKXQO7=TIP^0_6NJE14'>[^;N2W<\[_:;_:6
M^&O[+'PRN?B9\2M2*1(/+T[3X2#<:C<D96")3U8X))/"J"QX%?/7PA^,W_!2
M;]KG0[?XL_"ZQ\"?#7PC>V^='BU^VEU*YOL-@R?*4*J2&P2JY&"`00QY'_@N
MWX$\7:O\+O!?CG2I+V32-)UBXAU6W@@+0PO-&HBN)&!PI!4Q@D=9>"#@'Z3_
M`&!/B%X-^)7[(_@;6O!-O;6UM:>'X+"YL+5N+2X@01RQ$8&#N4GIR&!&003Q
M.I.KC94Y-I)77G_PQ25J:9YSXMTS_@K#\/-&D\6Z7X\^&?C>2SP[>&;?0)K.
M6\4Y!"2M*`"N0V,C=MP#G`.C^Q)_P4H^'W[6VMS?#G5/"=YX8\8VEF\T^DW,
MHE@N%0JLGDR<$E2>490P`SR`<?2MPVU\GIC)/I7Y/_L?6[?$+_@KIJ7B?X5W
M$MMI$7B;6[^XF@F:9)K0^:KDR*H&R61PRAOE^95YXI5IU,/5IQA)M2=K/4<4
MI)M]#]948.NX5\9_\$ZOVT_CM^TM^T)\1?AU\4M0TJ33/#4<ITM+#3!"Z[;Q
MX1N;<=WR@?CS7V7&/EW>M?FW_P`$;3C]L#XR?]<I_P#TY25OB9SCB:23T;=_
M/0E6Y6?I-5+Q%9:MJ&AW=EH6LC3[V6W=;6^-LLWD2$':^QL!\'!VDC/2KC-M
M[4,NX8KN)/@.V_X*(_M-_LK?M+O\'_V\=*TR;PY>X&G>)-`TEH8Q&7PMVF&;
MS8N0)$^_'R<''S?9OCOXX_"OX;_"JX^-/BWQG90>&H;);I=42821SQL`4\K;
MGS"^0%"Y+$@"L']J;]EGX8_M6_#.;X=?$>R*E=TNE:K;HOVC3;C&!-$Q_(J>
M&'![8_,?]EK]G'QM^T5^T;+^P[\4OC%J,W@OX;:EJ5W+I]M*PCG\BY2WD6$$
MGRO,9N"<^6K/M`+9KR*E3$X6?);FYOA?9^?D7925UT/K;]DW]J7]LC]M7XQW
M_CGP7IFF^$O@_IM_Y:37^D^=>W^P_P"ICD+X,C=78`I$#M&YA7TQ\==(^.VN
M^"TLOV??&6A:%KPO8V:]\0::]W;F`!MZ;$8'<25(.>Q]:Z/P3X)\+?#KPM8>
M"?!.B6VFZ3IELMO86-I$$CAC4<``?J>I/)R:U:[J5&:IVG)MO5_\#R);UN?%
MO[27B_\`X*:?LS?!C6?C7X@^.WPWU.ST983-96?@^999/,FCB&TM)@8,F>?2
MH/V7?'__``4R_:E^#6F_&GPS\<_AOI5GJ4UQ''97_@Z5Y4,4[Q$DK)CDH2,=
MC7IW_!5[_DPSQW_USL/_`$OMZSO^"0W_`"85X3/_`$_ZI_Z7SUR<C6-]GS.W
M+?<O[%SUW]GSP]^T-X>\-7L?[1_Q!T+Q!JTMYNLY?#VE-:00VX484AB69]VX
MD].F*\L_X*>_M+?%3]E?X"Z=\1/A'<V$.I7/B>WL)6U&R^T1F%X9W.%R.<QK
MS7TBJ[>]?&'_``7*;/[)6BG_`*GJT_\`26[K7%RE2P<G%ZI$P^(]Q_87^+_C
M7X]_LL>%/BY\1+BUEUG68+A[U[.V\J(E+J:-=J9./E1>_:MS]I7]I#X:?LM_
M#2[^*/Q-U4Q6T)\NRL8<&XO[@J2L$2D_,QP>>B@$D@"O/?\`@E;_`,F&^`/^
MO6\_]+KBO!_^"[O@OXA:Q\-O!?C#0K:YF\/Z1J5TNL^3N9()Y4C6":10,!<"
M5`Q(P9`!]ZI=:=/+_:+5V!1]ZQU'PS_:1_X*+?MCK!XT^`GPZ\+_``Y\&NQ^
MS:MXQ22]EU)"6Q)&B!=RC:!P`,MP[XP.\/A;_@JOX8/]KP?$_P"$WBAE^7^R
M+K1;NQ1\\;_.1F((ZXQSBNU_8*\5?#;Q5^R9X'E^%MY$^GV/ARULYK=9MSVU
MQ'&%FBD&YBK"0/D$]Z]DJZ-'VM)2<V[]GH'-9V,GP/'XRC\+6(^(4^G2:U]F
M4ZDVDQNEMYI&6$0D9FVCH"QR<9XS@?*7[;/_``4D\8?`KX_Z+^S)\'?AUINH
M>(=2DLEFU+Q'=R1V:&[D\N)%$7S'DY9R1M[*W4?8=>5_M(?L?_`#]JG3(]+^
M+W@B&\NH(3'9:Q:2>3>VBDDX25>=N<G:V4)Z@UKB(5G2M2=F)-)W9YA-\+/^
M"I&K7D/B!OVH_AWISQ9>+1[/PA)):RA\;DE=SO?RQ]QE*Y/WNM=-\#W_`."B
M%MXTL]%^/\/PQN?#T+S_`-H:SH<MVM]<#Y_*"0D"-"24SDG@'J37DTO_``3,
M_:/^&MO(G[.'[?WC'3((WADMM+U]WFA,B[0=[(^W9M4`)Y1&!@Y!KSO0/V_O
MVTOV9?VF-._9?_:/M?#_`(YDNM4M+:2^T5%%V8KF1@DB^2%7<-RDQO&I"IQG
M<&/%[3V#3J*2N[;W3;+4>?8_1JBBBO6,SY6_X*Y_`:Y^,?[)5]KVCZ6USJO@
M^[75[94`+M;J"MRHX)V^42Y`QGRAS6I_P2I_:`L?CA^R7HMC>:KYVM>$D71M
M81VR_P"['[B0Y))#1;/F/5E?TP/H^_M+>^M)+2[A62*5"DL;KE74C!!'<&OR
MU\5V/Q'_`."/_P"UTWC30]-;5?AQXQFF$%A;RE5>T#AS`1PJW-ON.PGAD)'&
MYMOEXA_5JZK_`&7H_+L_0TC[T7$_5#(/0T5S/PG^+'@+XU^";+XA_#;Q%:ZI
MI5_'NBN+697V-_%&^"=KJ>&4\@UTU>E&2DKK8S"BBBJ`*0LJ]3BACM4MBODW
M_@H__P`%$-$_9B\(R?#_`.&6JZ??^/\`4,PK;+,)#HT;)G[3*@S\QR`B-C).
M>0I!RK5H4*;G(:3D[(^;OVRM9@_;J_X*5^&/V?O",4EYHGAF\CTS4YXF9HV"
M2>=?2X#J`%0&+<""2N`22M?I]9VR6D"V\2;5C0*@!Z`=*^.O^"3_`.Q-J'P1
M\'3_`!^^*MLY\9^+[;S(X[D2>=I]G(1)LD#\B:1L.Y(R.%SP<_9=<F!I5.65
M2IO)_AT*FTW9=#R#]L;]D'PG^V9\/]/^'/C/Q3J>CVVG:PFHQ7&E"(R.ZQ2Q
M;3YBL-N)2>F>!7>?"3X>6'PD^&>@?"[2K^:ZM?#VC6VGV]S<A?,E2&-8PS;0
M!N(7)P`.:^4?VY_^"A_QL_9V_;M^$_['/PO\*Z5+9_$/P?K.M7^NS^#M5U^[
MLWL2@6.*QTV199%?<<OSMZGBNL_X)Y_\%"KG]K7QG\2_@G\0_#MIHGC;X9Z\
MEG>6)L[O3;C4[*6-9(=0_LV]07-E$X=5`D9PQ#%7X('8J4%/GZD'3?M@?\$\
M/@G^V->6.O\`BV6]T77+#$8UW11&)KB#G$,H=65U!.5)&Y>QP2*Z_P#9%_9=
M\,?LA_";_A4GA'Q)J&JV?]J3WPNM36,2[I=N5_=JJX&T8XS7J!.!FOFW]I?]
MN3Q%\$/V]/V=_P!CC1?`EE>VGQHE\2-JNN7-TXDTZ+2]/%PJQ1J,,SNZ@LQP
M%4X!)!$K#THU?:)>\-MM69](&)2"&P<C'(KYG^*G_!*_]G;QUXN;XD?#Z]US
MX>>(I)"\FI^";_[*KL6#.WE8*@L0<[=H.22">:^FJ\3_`."AG[8B_L%_LF>*
M?VHG^$^L>-/^$<@C8:)H[+'DNZH)9YF!6VMD+!I9R"(T!8@XJJE*%56D@3:V
M.8M?V"?B<+J-M3_;\^,EW;!Q]HMCK-NGFID;EW+%E<C(R.1G/:O5O@#\`-$_
M9Z\.77A3PYXX\4ZS97%SY\:^*=<:_DMV(PPCD=0X4\$J21GICG/SI^TQ^W-^
MUE^R%^SS=_MC_$[X7?#?Q/X'L=/LK[6O#OA+Q/=IJVFP37$,+_99Y8&@U9@)
M0P`6TRP"@MN!KZW\+>([7Q9X?L/$EE:W$$.HV,-W##=PF*9$D0.H=#RC`'!4
M]""*F%"G3=TOS!ML3Q3X7T+QCH-WX8\4:3;W^G7]L]O>V5W$'CFC88*LIX((
MKYKA_P""6O@/P-X@GUC]G7X[?$'X:6MY$!>:5X8UO=;RL-HWXG#L#A1G)/Y<
M5](^-(_%<WAN]@\"ZAI]IK#6S#3KG5;-[BVCE/1I(XY(W=1W"NI]Z^-OV<OV
MR_VX?CA^W3\:OV.M1O/A790?!-_#KZAK<'A34W?68]3M6N66-#J.+=HU0J"3
M("2#@`8+J4*51WDM03:V.YU#_@G-\1/$^C2>'O'/[?7Q>U.RN?EO[0:I#%'<
M1[\[#A"PR``<'GGCG%>O?L]?LI_!#]E_PZWASX.^"+?31.B"^OW)DNKQER0T
MLK?,W)8@?=&>`*]&5MPSCO7F?[:'QNUO]FC]D?XF?M$^&M'M-1U#P+X#U77K
M*POBPAN9;2TDG2-RA#!69`"00<=*F.'I0=T@;;/3:^/_``O_`,$C]!\`^.]6
M^(GPT_:H^(GAK4]8GG>\GT6>VA+++*96C)$7S*&Z9R>!SG).W^QC^U!^T7\>
M=2T.[^)=WI%O!>^'DU'5-.M/@UXDT=$=XU/EP:AJ4HAE"NX_Y9[G12P5>WU*
M#D9IU:%*LTYJ]M@3:V/FD_L%?%;M_P`%#_C-_P"#6V_^-5[_`."O#5SX0\+:
M=X;GUV]U62PLHX)-1U.<R7%TRJ`99&/5F.2>W/&!7D?[?_[;&@_L+?!W3OB7
MK'@RXUFXUSQ18>']*66X^QZ=:W5W,L23ZA?,K1V%JI.6F<'G:JJS,!73_!B_
M_:7U#5[C4_CEJ_P[BL+N*1M,T;P:M[<2P`2?(SWMPZ+<#8#G;;189L#(7EPH
MPIN\0O<],KP#X&?L`^!/@3^TCXH_:6T'QQK5]J?BG[=]JTZ]2#[/#]JN4N&V
M%$#\%`HR3P>:]_KY^_;T_;*UW]CFY^$=UI7P^N_$=IX_^*UKX5UBVTO3+B]O
MK>UFL;RX,]M!;Y>616MD)4*WR;R%)`ISI0G).2VU0)M;'T#17QOXJ_X*@ZJ/
M^"COP-_8N\$?"O5X-$^*&B^)+O7-8\9^#M6T6\M)-.M%GB6U6\AA68.20Y`;
M:-O(R,_9%:"."_:5^`NB_M+?!C6/@MXCUV[TVRUD0B>]L%0S1B.9)1MW@KR4
M`Y!ZU7_9=_9YT']EKX.:9\%_"^NWNIV6F37,D5[J(02N9IGE(.Q0O!<@8'05
MZ+167L::J<]M;6`*\E_;`_9,\+?MC?#>T^&'C'Q-J.D6EIK$6HI<:6L9D9TC
ME0*?,5AMQ*3TSP*]:KYG_8U_;=\;?M)?MB?M+_LV>)/!VE:?IWP/\5:)I6B:
MA8O(9]1CO;!KEWG#,54JR[1L`&.O/-5.$:D7&6P'KW[-_P`"]%_9L^#6B_!;
MP[K5WJ%EH<<J07E\$$LHDF>4[M@"Y!<C@#@5UGB'PUH?BS1+OPUXETJVO]/O
MK=X+VRNX%DBGC889&5L@@CL:O5\K_MO_`+;'[0?[./[1GPV^$'P,^`5C\08?
M$OA;Q'X@\0Z+'?M!JT]II9L`T.FDGR7N"+TN(YMJR>5L#*S`T*G%14>B`2Y_
MX)4?#+POX\N?'G[/?QB\;_#&2]C*WECX2U55MWSZ+*K%5ZX7.%S\N.E:3?\`
M!/#Q%KW_`!+_`(B?MM_&/7=+89DTY_$B6VYQRK>9#&&&#SC/-<S^S)_P5!M?
MVK_VY4_9Z^&?@`Q>!I?@J/&$?B/5(YK?4EU5-3CLKG2I[5POV:6W#KYJ/EPS
M+_"06^O:Q^J4%LBN:1S_`,-_`%K\,O`VF>`M-UO5-1M]*MA!!>ZU?FYNI4!.
M/,E89<@<9/8"O'OC;_P3Y\#?&OQSJOQ*NOC)\1M#UO5(HHQ-H?BN2&WMA$N(
MPD`&W:"6;:<C+L>]'[;?[<L7[)?B?X6?#G2_`D6L>(/BYXU/AOPY<ZOJ;:?I
M%E,L+3,]Y=K#,8BP4)$BQLTCG`P`2/0/@A<?'YM,EG_:!\0^"+F]NHHI+.T\
M&6-U'';<-YB-+<3.UP`2H601PYP24&0!I*C3E'E:T$FUL>1#]@?XW_VJSK_P
M44^+GV'[,%6'[;!YOG;L[M^S:4VX&W;G/.[M6Y\!_P#@F]^S[\#?'+_%F:+5
M/%GB^5Q/+XC\67:W4RW.27N(UVA8Y&)Y8#(P`"!G/T%45Q>06SHDLJJ7.$#,
M,L?0#O4+"T8N]OOU'S2):***Z"0(!ZBN.^.'P,^&_P"T3\.[[X8?%+P['?Z5
M?*"1G;+!*/N31/UCD4\AA].02#V-%3*,9Q:DKH#\Q/$'[/'[='_!,KXA:CXX
M_9C:\\6_#^:X,UQIPC-RK1@8Q=VT>&$BCY1/%Q@9.!A:]F^"/_!;']G#QGI=
MM:_&/2M4\'ZJ6*73+:O>68(0G>'B&\`D8VE,@D#G[U?:30(WKP<UX_\`%C]@
M?]D7XTYF\<_!+1C<F3>U]I<)L9V8L6;=);E&;)))SG.>:\_ZI7P[OAY:=GLO
M0MSC+<F7]O7]C)E#C]I_P4`PR,Z_"/YFN?\`B+_P4R_8E^'&CC5[GX[:3JS-
MGRK/PZYOIG(QQMBR%Z]7*@XX.>*\W;_@A_\`L=,Q8:]XX7)Z+KD.![?\>];'
M@K_@C3^Q3X1U3^U-1T+7_$&'1X[;7=;+1(5;/W85C#@]"K[@1VH<\R>G+%?-
MBM3[GAOQ<_X*Z?&GX[>+5^#W[#/PJO1=WLOE6^K7MH)[V3+!=\</,4"C/WY2
M0,Y(6N]_8?\`^"5\W@SQ3%^T/^UAJG_"0>-GNY+R+29YQ<P6L[-N6XF<C]_.
M#D_W%)&,E01];_#/X(?"7X,Z4=%^%/P[T?P_;,`)$TJP2(R`$D;V`W/@L<;B
M<5U*1JF=O>G2P4I252O+F?X+T\PYK;"H"%&[KCFEHHKT23SCXR_LE_L]?'_Q
M+HOC7XM_"O3=7UOP[#/#H6MDR07MA'.`LT<5Q"R2*C@`,N[:<=*W_AE\%_A/
M\&]/N-*^%/PST#PU;W4WG7<6A:1#:BXEVA?,D\M1YCD*H+-DG`YX%=110`5R
MOB_X+?"GQUX\\+_%+Q?\/M)U'Q)X+GN9O"FN75DK7.E/<0F"<PR?>021L58`
MX(QGH,=510`V/=L`88-4_$GAK0/&.@WGA;Q7HEGJ6F:A;/;ZAIVH6J3P7,+J
M5>.2-P5=&4D%2""#S5ZB@#RS2/V(_P!D7P]JUOK>B_LS^!89[*>.?3B/"]J4
MT^5"&#VR%"ELVX!R8@A9@&.6&:]3HHH`"`>HKD_#7P1^%7A'XF>(OC+X:^'^
MDZ?XJ\6VUI!XFUZTLU2YU-+576W$S#[_`):R.JD\@''0`5UE%`!6-\0_A]X.
M^*W@?5_AK\0_#UKJ^@Z]IL^GZSI5]%OAO+69"DL3KW5D)4CT)K9HH`\$^!__
M``3$_8)_9L^(=E\6/@3^ROX3\,>(]-CECL=7TNT9)H5DC,;A26(`*,R_0U[W
M110!G>+?"'A3Q]X<O/!_CCPUI^LZ3J$!AO\`2]5LH[BWN8SU22.0%77@<$$5
MP_PM_9'_`&:_@GXB?Q-\)O@;X9T"^9IC%=:9I,<36JRG,L<&!_H\;M\S1Q;$
M9B6*DDFO2:*`"N=\;?"GX??$K4_#^L>/?"-CJESX4UQ=8\.37D6YM/OEBDA6
MXCY^5Q'-*N?1S7144`<GK_P0^%'B?XI:%\;=?^'VDWOBWPSI]Y8^'O$-U:*]
MUIUO=;/M$<+GF,2>6@;')`QT)%=6N=HR,&EHH`****`"N5\#_!7X6?#/Q5XG
M\<^`/`.E:5K/C74XM0\6ZI8V:QSZK<QPK"DL[CF0K&BJ,\`9QR23U5%`!7.:
MS\)OAYK_`,1M%^+>L>#[*Y\2^';"[LM$UJ6+,]G!=&(W$:-V63R(=WKY:UT=
M%`'":%^S3\"?#GQQU7]I;0_A1H=GX^US1TTK6/%EM8JE[>V:LCK#+(,;P#&G
M)Y^11G"@#NZ**`,+XC?#+X=?%OPT_@SXI>`-%\2Z1+,DLFEZ_I4-[;,Z'<CF
M*960LIY!(X/(KEOA7^RA^SO\#M8EU_X0_!7PWX>O)A,IN=-TM$DB2:3S)(8F
MQF"%I/G,,>V/<2VW))KT:B@`KEO&OP9^%GQ%\5^'_''CGX<:)K&L>$[F2Y\,
MZIJ>FQSSZ7-(`'D@=P3$QVKRN#\H]!74T4`%%%%`!1110`4444GL`4444=0"
MBBBA;`%%%%,`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
BHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
